The phenomenon of osteonecrosis of the jaw in patients with metastatic breast cancer

Cancer Investigation

Volumn 24, Issue 1, 2006, Pages 110-112

  Van Poznak, Catherine ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Bisphosphonate associated osteonecrosis; Osteonecrosis of the jaw

Indexed keywords

ANTIBIOTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CHLORHEXIDINE; CORTICOSTEROID; PAMIDRONIC ACID; ZOLEDRONIC ACID;

BISPHOSPHONATE ASSOCIATED OSTEONECROSIS; BONE NECROSIS; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; DEBRIDEMENT; HUMAN; HYPERCALCEMIA; INCIDENCE; JAW OSTEONECROSIS; PATHOGENESIS; PRIORITY JOURNAL; SHORT SURVEY; SKELETAL RELATED EVENT; TOXICITY;

BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BREAST NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; JAW DISEASES; OSTEONECROSIS;

EID: 32644481945     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900500449652     Document Type: Short Survey

References (23)

1. Mont, M.A.; Jones, L.C.; Einhorn, T.A.; Hungerford, D.S.; Reddi, A.H. Osteonecrosis of the femoral head: potential treatment with growth and differentiation factors. Clin. Orthop. 1998, 355 (Suppl.), S314-S335.
2. Assouline-Dayan, Y.; Chang, C.; Greenspan, A.; Shoenfeld, Y.; Gershwin, M.E. Pathogenesis and natural history of osteonecrosis. Semin. Arthritis Rheum. 2002, 32, 94-124.
3. Marx, R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J. Oral Maxillofac. Surg. 2003, 61, 1115-1118.
4. Mehrotra, B.; Fantasia, J.; Nissel-Horowitz, S.; Vinarsky, S.; Sheth, M.; Ruggiero S. Osteonecrosis of the maxilla: an unusual complication of prolonged bisphosphonate therapy. A case report. Proc. Am. Soc. Clin. Oncol. 2003, 22, 795 (Abstr. 3194).
5. Ruggiero, S.L.; Mehrotra, B.; Rosenberg, T.J.; Engroff, S.L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J. Oral Maxillofac. Surg. 2004, 62, 527-534.
6. Estilo, C.L.; Van Poznak, C.; Williams, T.; Evtimovska, E.; Tkach, L.; Halpern, J.L.; Tunick, S.J.; Huryn, J.M. Osteonecrosis of the maxilla and mandible in patients treated with bisphosphonates: A retrospective study [Abstract]. Am. Soc. Clin. Oncol. 2004, 8088.
7. Domchek, S.M.; Younger, J.; Finkelstein, D.M.; Seiden, M.V. Predictors of skeletal complications in patients with metastatic breast carcinoma. Cancer 2000, 89, 363-368.
8. Body, J.J. Effectiveness and cost of bisphosphonate therapy in tumor bone disease. Cancer. 2003, 97 (3 Suppl), 859-865.
9. Lipton, A. Colombo-Berra, A.; Bukowski, R.M.; Rosen, L.; Zheng, M.; Urbanowitz, G.; Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid. Clin. Can. Res. 2004, 10, 6397S-403S.
10. Rosen, L.; Harland, S.J. Oosterlinck, W. Broad clinical activity of zoledronic acid in osteolytic to osteoblastic bone lesions in patients with a broad range of solid tumors. Am. J. Clin. Onc. 2002, 25 (6 Suppl 1), SI9-24.
11. Saad, F.; Gleason, D.M.; Murray, R.; et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl. Cancer, Inst. 2002, 94, 1458-1468.
12. Berenson, J.R. Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist. 2005, 10 (I), 52-62.
13. Migliorati, C.A.; Schubert, M.M.; Peterson, D.E.; Seneda, L.M. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone. Cancer. 2005, 104, 83-93.
14. Maerevoet, M.M.; Lenoir, J.J.; Degols, L.; Duprez, P.; Donnay, M.; Duck, L. Ten Cases of Osteonecrosis of the Jaws following a Treatment by Diphosphonate within the framework of Bone Metastasis of Breast Cancer and Multiple Myeloma: Experience in summer 2004 of a Single center. J. Clin. Oncol. (suppl) 2005, 23 (16S), 796 (abstract 8271).
15. Brian, G.M.; Durie, B.G.M.; Michael, Katz, Jason, McCoy, and John, Crowley. Osteonecrosis of the Jaws in Myeloma: Time Dependent Correlation with Aredia® and Zometa® Use. Blood (ASH Annual Meeting Abstracts). 2004, 104, 756.
16. Wang, J.; Goodger, N.M.; Pogrel, M.A. Osteonecrosis of the jaw associdated with cancer chemotherapy. J. Oral. Maxillofac. Surg. 2003, 61, 1104-1107.
17. Van Poznak, C.H.; Estilo, C.L.; Sauter, N.P.; Hudis, C.A.; Williams, T.; Tunick, S.; Halpern, J.; Huyrn, J.M. Osteonecrosis of the jaw in patients with metastatic breast cancer. Breast Cancer Res. Treat 2004, 88 (supp 1), S131-3057
18. Hoff, A.O.; Toth, B.B.; Altundag, K.; Adamus, K.; Adamus, A.; Nooka, A.; Desrouleaux, K.; Cui, J.; Gagel, R.F.; Hortobagyi, G.N. Osteonecrosis of the jaw in patients receiving intravenous bisphopshonate therapy. Presented at Skeletal Complications of Malignancy (IV). Natcher Conference Center, NHI, April 28-30, 2005. Abstract 80.
19. Bone, H.G.; Hosking, D.; Devogelaer, J.P.; Tucci, J.R.; Emkey, R.D.; Tonino, R.P.; Rodriguez-Portales, J.A.; Downs, R.W.; Gupta, J.; Santora, A.C.; Liberman, U.A.; Alendronate Phase III Osteoporosis Treatment Study Group. Ten years' experience with alendronate for osteoporosis in postmenopausal women New Engl. J. Med. 2004, 350 (12), 1189-1199.
20. Sorensen, O.H.; Crawford, G.M.; Mulder, H.; Hosking, D.J.; Gennari, C.; Mellstrom, D.; Pack, S.; Wenderoth, D.; Cooper, C.; Reginster, J.Y. Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone. 2003, 32 (2), 120-126,
21. Agarwala, S.; Jain, D.; Joshi, V.R.; Sule, A. Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study. Rheumatology. 2005, 44 (3), 352-359.
22. Prockop, D.J. Type II collagen and avascular necrosis of the femoral head. New Engl. J. Med. 2005, 352 (22), 2268-2270.
23. http://www.fda.gov/medwatch/getforms.htm. Accessed 12-20-05.